On August 5th, the official website of the National Medical Products Administration (NMPA) of China announced that the anti PD-1 antibody drug, Paprilimab (AK105), jointly declared by Kangfang Biotechnology and Zhengda Tianqing, has been approved. According to public information, the indications for the approval of piazeprizumab this time are: for the treatment of recurrent or refractory classic cases that have undergone at least second-line systemic chemotherapy
Recently (August 9, 2021), according to CDE announcement, BBM-H901 injection from Xinzhi Pharmaceutical Technology has been approved for clinical use in type B hemophilia.
Type B hemophilia is a type of hemophilia caused by a lack of coagulation factor IX, accounting for approximately 15% of the total number of hemophiliacs. The most common treatment method is intravenous injection of concentrated factor
On August 8, 2021, Rongchang Biotechnology (09995. HK) reached a global exclusive licensing agreement with internationally renowned biopharmaceutical company Seagen Inc. (SGEN) to develop and commercialize its ADC new drug, vidiximab.
Although the Federal Trade Commission (FTC) of the United States has sued to block this transaction, and the European Union is also launching an antitrust investigation, the acquisition case has still been completed.